A 43-year-old man presents to his endocrinologist reporting progressive enlargement of his hands and feet over the past 4 years, requiring multiple ring and shoe size increases. He also notes excessive sweating, fatigue, and was recently found to have fasting glucose of 142 mg/dL on routine labs. Physical examination reveals coarse facial features with frontal bossing, a prominent jaw, widely spaced teeth, and a soft tissue mass effect causing mild bitemporal hemianopia. His IGF-1 level is markedly elevated at 890 ng/mL (normal <200 ng/mL), and random growth hormone fails to suppress below 1 ng/mL following an oral glucose tolerance test. MRI of the pituitary reveals a 1.4 cm macroadenoma with suprasellar extension. Surgical resection is deferred due to the patient's comorbidities, and he is started on a long-acting somatostatin analogue known to suppress growth hormone release and also used in the management of carcinoid syndrome and esophageal variceal bleeding. Which of the following drugs was most likely prescribed?

1. A)OctreotideGABARITO
2. B)Cabergoline
3. C)Pegvisomant
4. D)Desmopressin
5. E)Leuprolide